## This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

## Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Currently Amended) A method of treating an organ with a thrombolytic agent to promote thrombolysis <u>and/or prevent</u> the formation of new thrombi, <u>said method</u> comprising perfusing said organ <u>ex vivo</u> with a perfusion solution comprising a thrombolytic agent.
- 2. (Original) The method according to claim 1, wherein the organ is an organ removed from a human.
- 3. (Currently Amended) The A method according to claim 1, wherein said perfusion comprises of treating an organ with a thrombolytic agent to promote thrombolysis and/or prevent the formation of new thrombi, said method comprising:
  - a). connecting said organ to a perfusion circuit, and
- b) recirculating the perfusing the organ with a perfusion solution comprising a thrombolytic agent, wherein the perfusion solution is circulated through the organ,
- c) measuring at least one parameter that indicates a level of thrombolysis, and
  - d) determining whether thrombolysis occurs.
  - 4. (Canceled)
- 5. (Currently Amended) The method according to claim 1, wherein the thrombolytic agent is selected from the group consisting of Streptokinase; Urokinase; Alteplase, Tenecteplase, other-recombinant tissue plasminogen activators, Anistreptase, anisoylated streptokinase, Reteplase, and other-mutant-tPAs tissue plasminogen activator, and mixtures thereof.

- 6. (Original) The method according to claim 1, wherein the thrombolytic agent is Streptokinase.
- 7. (Original) The method according to claim 6, wherein an amount of the thrombolytic agent used is between 10,000 to 1,500,000 IU.
- 8. (Original) The method according to claim 6, wherein an amount of the thrombolytic agent used is between 100,000 to 300,000 IU.
- 9. (Currently Amended) The method according to claim 1, wherein an amount of the thrombolytic agent used is from about 5,000 to about 58,000,000 IU, or from about 10 to about 30 or more Units.
- 10. (Original) The method according to claim 1, wherein an amount of the thrombolytic agent used is about 250,000 IU.
- 11. (Original) The method according to claim 1, wherein the perfusion solution further contains a vasodilator.
- 12. (Original) The method according to claim 3, wherein the perfusion circuit has a systolic pressure of less than 60 mm Hg.
- 13. (Original) The method according to claim 3, wherein the perfusion circuit has a systolic pressure between 45 mm Hg and 60 mm Hg.
- 14. (Original) The method according to claim 3, wherein the perfusion circuit has a systolic pressure of about 50 mm Hg.
- 15. (Currently Amended) The method according to claim 3, wherein the perfusion solution is recirculated at a temperature between 2°C and 10°C.
- 16. (Currently Amended) The method according to claim 3, wherein the perfusion solution is recirculated at a temperature of about 5°C.
- 17. (Currently Amended) The method according to claim 1, wherein the organ is perfused with said perfusion solution for 1 to 20 hours.

- 18. (Currently Amended) The method according to claim 1, wherein the organ is perfused with said perfusion solution for at least 4 hours.
- 19. (Currently Amended) The method according to claim 1, wherein the organ is perfused with said perfusion solution for 4 to 12 hours.
- 20. (Original) The method according to claim 1, wherein the organ is selected from the group consisting of heart, liver, kidney, lung, pancreas and intestine.
  - 21-43. (Canceled)
  - 44. (New) The method according to claim 20, wherein the organ is a kidney.
- 45. (New) The method according to claim 1, wherein an amount of the thrombolytic agent used is from about 10 to about 30 or more Units.
- 46. (New) The method according to claim 1, wherein the perfusion solution is circulated through the organ ex vivo.
- 47. (New) The method according to claim 46, wherein the perfusion solution is circulated through the organ *ex vivo* using a perfusion circuit.
- 48. (New) The method according to claim 1, wherein said perfusion solution contains at least 10,000 IU thrombolytic agent.
- 49. (New) The method according to claim 3, wherein the organ is an organ removed from a human.
- 50. (New) The method according to claim 3, wherein the thrombolytic agent is selected from the group consisting of Streptokinase, Urokinase, Alteplase, Tenecteplase, recombinant tissue plasminogen activator, Anistreptase, anisoylated streptokinase, Reteplase, mutant tissue plasminogen activator, and mixtures thereof.
- 51. (New) The method according to claim 3, wherein the thrombolytic agent is Streptokinase.

- 52. (New) The method according to claim 51, wherein an amount of the thrombolytic agent used is between 10,000 to 1,500,000 IU.
- 53. (New) The method according to claim 51, wherein an amount of the thrombolytic agent used is between 100,000 to 300,000 IU.
- 54. (New) The method according to claim 3, wherein an amount of the thrombolytic agent used is from about 5,000 to about 58,000,000 IU.
- 55. (New) The method according to claim 3, wherein an amount of the thrombolytic agent used is about 250,000 IU.
- 56. (New) The method according to claim 3, wherein the perfusion solution further contains a vasodilator.
- 57. (New) The method according to claim 3, wherein the organ is perfused with said perfusion solution for 1 to 20 hours.
- 58. (New) The method according to claim 3, wherein the organ is perfused with said perfusion solution for at least 4 hours.
- 59. (New) The method according to claim 3, wherein the organ is perfused with said perfusion solution for 4 to 12 hours.
- 60. (New) The method according to claim 3, wherein the organ is selected from the group consisting of heart, liver, kidney, lung, pancreas and intestine.
  - 61. (New) The method according to claim 20, wherein the organ is a kidney.
- 62. (New) The method according to claim 1, wherein an amount of the thrombolytic agent used is from about 10 to about 30 or more Units.
- 63. (New) The method according to claim 1, wherein said perfusion solution contains at least 10,000 IU thrombolytic agent.